Quetiapine and Cortisol
Quetiapine decreases, not increases, serum cortisol levels through its effects on the hypothalamic-pituitary-adrenal (HPA) axis, and this reduction should be monitored in patients with cortisol-sensitive conditions to avoid potential hypocortisolism.
Effect on Cortisol Levels
Quetiapine has a well-documented cortisol-lowering effect. In a randomized, double-blind, placebo-controlled study of healthy volunteers, quetiapine (50 mg) significantly reduced both ACTH and cortisol secretion compared to placebo 1. This effect was observed within hours of administration, with cortisol decreasing from 150 minutes post-dose through the end of the observation period 2. The mechanism likely involves quetiapine's antagonism of serotonergic receptors (particularly 5-HT2), though blockade of adrenergic or histaminergic receptors may also contribute 1.
Clinical Significance
The cortisol reduction is clinically meaningful:
- A case report documented reversible hypocortisolism in a patient using quetiapine, with low early morning cortisol levels and abnormal tetracosactide testing that normalized after quetiapine discontinuation 3
- The HPA-axis down-regulation may contribute to quetiapine's therapeutic effects on depressive symptoms and cognitive functioning 1
- This effect occurs even at low doses (25-75 mg/day), where cortisol reduction may be a therapeutic mechanism 4
Management in Cortisol-Sensitive Conditions
Patients to Monitor Closely
Avoid or use extreme caution in patients with:
- Pre-existing adrenal insufficiency (primary or secondary)
- Glucocorticoid-induced adrenal insufficiency recovering from exogenous steroid use
- History of hypopituitarism
- Concurrent use of other medications that suppress the HPA axis
Monitoring Protocol
For patients requiring quetiapine who have cortisol-sensitive conditions:
Baseline Assessment
- Measure morning cortisol (ideally between 0800-0900 hours) before initiating quetiapine
- Consider baseline ACTH if secondary adrenal insufficiency is suspected
- Document symptoms of adrenal insufficiency (fatigue, malaise, weakness, hypotension)
During Treatment
- Recheck morning cortisol at 2-4 weeks after initiation or dose escalation
- Monitor for symptoms of hypocortisolism: persistent fatigue, malaise, orthostatic hypotension, nausea
- Use cortisol values as a continuum rather than arbitrary cutoffs 5
- Morning cortisol <150 nmol/L (5 μg/dL) indicates likely persistent adrenal insufficiency 5
- Morning cortisol >300 nmol/L (10 μg/dL) suggests adequate HPA function 5
If Hypocortisolism Develops
- Temporarily treat with physiologic hydrocortisone replacement
- Taper quetiapine if clinically feasible 3
- Reassess cortisol production after quetiapine discontinuation
- If quetiapine must be continued, maintain lowest effective dose with glucocorticoid replacement
Important Caveats
Assay considerations: Cortisol measurement varies by assay method. Immunoassays can differ by up to 170 nmol/L in cutoff values compared to mass spectrometry 5. Familiarize yourself with your laboratory's specific reference ranges and methodology.
Confounding factors that affect cortisol interpretation 5:
- Disrupted circadian rhythm (night shift work, severe insomnia) can falsely lower morning cortisol
- Oral estrogens elevate cortisol-binding globulin, increasing total cortisol without affecting free cortisol 6
- Hypoalbuminemic states (cirrhosis, nephrotic syndrome) decrease measured cortisol
- Timing: ensure samples are drawn at least 24 hours after last glucocorticoid dose (excluding dexamethasone)
Contraindication Context
While the FDA label for quetiapine does not specifically list adrenal insufficiency as a contraindication 7, the documented cortisol-lowering effect 1, 2 and case report of quetiapine-induced hypocortisolism 3 warrant extreme caution in patients with compromised HPA axis function.
The key clinical principle: Quetiapine's cortisol-lowering effect is opposite to what the question implies—it does not increase cortisol but rather suppresses it, creating risk in patients who cannot tolerate further HPA axis suppression.